A phase II randomised, double-blind, controlled study to evaluate the safety and efficacy of PROSTVAC-VF/TRICOM in combination with GM-CSF [granulocyte-macrophage colony-stimulating factors] in patients with androgen-independent adenocarcinoma of the prostate

Trial Profile

A phase II randomised, double-blind, controlled study to evaluate the safety and efficacy of PROSTVAC-VF/TRICOM in combination with GM-CSF [granulocyte-macrophage colony-stimulating factors] in patients with androgen-independent adenocarcinoma of the prostate

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Granulocyte macrophage colony stimulating factor
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Therion Biologics
  • Most Recent Events

    • 30 May 2014 Results on immune response presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 28 Jul 2011 Results have been reported in Vaccine, according to a Bavarian Nordic media release.
    • 30 Apr 2010 On the basis of these trial results, PROSTVAC has been granted Fast Track status by the FDA for the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top